Comparison · NCT03172702-sae
Correction Phase vs Maintenance Phase: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Correction Phase vs Maintenance Phase: serious adverse events. Trial comparisons, record NCT03172702-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03172702-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00667 | 0.00118 | 0.0368 | wilson | |
| Risk in group 2 | 0.18 | 0.127 | 0.249 | wilson | |
| Risk difference, group 1 minus group 2 | -0.173 | -0.243 | -0.112 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.037 | 0.0051 | 0.269 | log | |
| Odds ratio, group 1 over group 2 | 0.0306 | 0.0041 | 0.228 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Correction Phase than on Maintenance Phase | 5.77 | 4.12 | 8.92 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Correction Phase | CP (up to 3 days):~Patients received 10 g ZS TID for a maximum of 72 hours. | 1 | 150 | EG000 |
| Group 2 | Maintenance Phase | MP (up to 12 months):~Patients received a starting dose of 5 g ZS QD which could be increased to 10 g or 15 g QD or decreased to 5 g QOD or 2.5 g QD. | 27 | 150 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- For the CP, from Day 1 to last CP dose + 1 day or first MP dose -1 day. For the MP, from the first MP dose up to 1 day (2 days for QOD regimen) after last MP dose. Overall, approximately 12 months.
Source ClinicalTrials.gov
Trial
- Title
- Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia
- NCT number
- NCT03172702
- Phases
- PHASE3
- Conditions
- Hyperkalemia
- Interventions
- Zirconium Cyclosilicate
- Lead sponsor
- AstraZeneca
- Results first posted
- 2020-05-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03172702?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03172702-sae